Risk Factors for Late-Life Cognitive Decline and Variation with Age and Sex in the Sydney Memory and Ageing Study

Darren M. Lipnicki1, Perminder S. Sachdev1,2,3,4, John Crawford1, Simone Reppermund1, Nicole A. Kochan1,2, Julian N. Trollor1,4, Brian Draper1,3,5, Melissa J. Slavin1,3, Kristan Kang1, Ora Lux1,6, Karen A. Mather1,2, Henry Brodaty1,3,5

1 Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine, University of New South Wales, Australia, 2 Neuropsychiatric Institute, Prince of Wales Hospital, New South Wales, Australia, 3 Primary Dementia Collaborative Research Centre, School of Psychiatry, Faculty of Medicine, University of New South Wales, Australia, 4 Department of Developmental Disability Neuropsychiatry, School of Psychiatry, Faculty of Medicine, University of New South Wales, Australia, 5 Academic Department for Old Age Psychiatry, Prince of Wales Hospital, New South Wales, Australia, 6 South-Eastern Area Laboratory Services, Prince of Wales Hospital, New South Wales, Australia

Abstract

Introduction: An aging population brings increasing burdens and costs to individuals and society arising from late-life cognitive decline, the causes of which are unclear. We aimed to identify factors predicting late-life cognitive decline.

Methods: Participants were 889 community-dwelling 70–90-year-olds from the Sydney Memory and Ageing Study with comprehensive neuropsychological assessments at baseline and a 2-year follow-up and initially without dementia. Cognitive decline was considered as incident mild cognitive impairment (MCI) or dementia, as well as decreases in attention/processing speed, executive function, memory, and global cognition. Associations with baseline demographic, lifestyle, health and medical factors were determined.

Results: All cognitive measures showed decline and 14% of participants developed incident MCI or dementia. Across all participants, risk factors for decline included older age and poorer smelling ability most prominently, but also more education, history of depression, being male, higher homocysteine, coronary artery disease, arthritis, low health status, and stroke. Protective factors included marriage, kidney disease, and antidepressant use. For some of these factors the association varied with age or differed between men and women. Additional risk and protective factors that were strictly age- and/or sex-dependent were also identified. We found salient population attributable risks (8.7–49.5%) for older age, being male or unmarried, poor smelling ability, coronary artery disease, arthritis, stroke, and high homocysteine.

Discussion: Preventing or treating conditions typically associated with aging might reduce population-wide late-life cognitive decline. Interventions tailored to particular age and sex groups may offer further benefits.

Introduction

Late-life cognitive decline ranges from normal age-related change at its mildest, through mild cognitive impairment (MCI), to dementia at its most severe. While the personal and societal impacts of dementia are substantial, even relatively mild cognitive decline can generate significant levels of functional dependence [1] and reduce quality of life. Mitigating cognitive decline requires knowing its causes, but a recent systematic review [2] found the evidence for putative risk and protective factors reported by observational studies to be inconsistent or only poorly supported. This could be because associations with cognitive decline are complicated by effects that vary with age [2], sex [3,4] and cognitive measure [5–8].

We recently reported that age and sex influenced cross-sectional risk profiles for MCI and its subtypes among population-based elderly individuals [9,10]. The current study used the same sample to identify factors longitudinally associated with late-life cognitive decline. A focus on effects varying with age or sex was maintained, and we again investigated a broad range of factors that included sociodemographic characteristics and lifestyle, medications, cardiac, physical, mental and general health, and biochemical indices of...
health. Importantly, this included a number of factors frequently associated with poorer cognition in the elderly, including apolipoprotein E (APOE) ε4 status [2] and smelling ability [8,11–13]. Cognitive decline was defined as worsening performance on measures addressing attention/processing speed, executive function, memory and global ability, and as a diagnosis of incident MCI or dementia. For significant associations between factors and decline we calculated the population attributable risk (PAR). This statistic considers prevalence in addition to strength of association, and may help identify interventions offering the greatest population-wide benefits.

Methods

Participants
Participants were from the longitudinal, community-based Sydney Memory and Ageing Study (MAS), described in detail elsewhere [14]. Briefly, the overall sample comprised 1037 individuals recruited randomly through the electoral roll who were 70–90 years old, non-demented, living in the community, and sufficiently competent in English to complete assessments. Exclusion criteria included a history of psychosis, intellectual handicap, multiple sclerosis, motor neuron disease, progressive malignancy, a Mini-Mental State Examination [15] score <24 after adjustment for age, non-English speaking background and education [16], and a diagnosis of dementia. All participants were assessed at baseline, and 889 assessed again at a 2-year follow-up (mean duration 23 months, 12 days). Of those not assessed at follow-up, 43 were deceased and 105 declined to participate.

Ethics Statement
The study was approved by the ethics committees of the University of New South Wales and the South Eastern Sydney and Illawarra Area Health Service. Written, informed consent was obtained from each participant.

Cognitive Domain and Global Cognition Scores
Trained psychology graduates administered a battery of neuropsychological tests from particular cognitive domains: attention/processing speed (Digit-Symbol Coding [17], Trail Making Test A [18]), memory (Logical Memory Story A [19], Rey Auditory Verbal Learning Test [18], Benton Visual Retention Test [20]), language (Boston Naming Test [21], Semantic Fluency [18]), and executive function (Controlled Oral Word Association Test [18], Trail Making Test B [18]). A more detailed account is given elsewhere [14].

Raw test scores were transformed to z-scores using the baseline means and SDs of a subgroup having fluent spoken English before the age of 10 years and classified as cognitively normal at baseline (n = 504). Domain scores were calculated by averaging the z-scores of component tests, and subsequently transformed so the means and SDs of the cognitively normal subgroup were 0 and 1. Global cognition scores were calculated by averaging across the domain scores (provided that no more than one of these was missing), and then similarly transformed.

Cognitive Status
Consensus diagnoses of MCI were made by a panel of psychogeriatricians, neuropsychiatrists and clinical and research neuropsychologists using current international consensus criteria [22]. MCI was diagnosed in individuals meeting all of: self or informant complaint of memory or other cognitive function decline; objective cognitive impairment (at least one test score 1.5 SD or more below published normative values, adjusted for age and/or education where possible); no dementia on the basis of DSM-IV criteria [23]; and no or minimal impairment in instrumental activities of daily living attributable to cognitive impairment (total average score <3.0 on the Bayer Activity of Daily Living (ADL) Scale [24] adjusted for physical impairment). Participants not classified as having MCI or dementia were deemed to have normal cognition.

Risk and Protective Factors
Table 1 shows the putative risk and protective factors investigated. Some data were obtained via interviews and questionnaires, including the 15-item Geriatric Depression Scale [25] and in most cases (93.9%) supplemented by an informant. Physical examinations by trained research assistants included measures of seated blood pressure, height and weight, a 6-m timed walk [26], and the Brief Snell Identification Test [27]. Venous blood was obtained after overnight fasting and stored in aliquots frozen at ~80°C, with total cholesterol, homocysteine and creatinine measured from heparin plasma aliquots using a Beckman LX20 Analyser by a timed-endpoint method (Fullerton, California, USA). EDTA plasma aliquots using reverse phase HPLC with fluorometric detection after derivatization with 4-aminoethylfluorobenz-2-oxa1,3-diazole (coefficient of variation = 6.7% at 11.7 μmol/L and 6.0% at 30.0 μmol/L) (BioRad Munich, Germany) and the Jaffe rate method, respectively. Standard procedures were used for APOE genotyping, as previously described [14].

Our factor definitions included the following. Non-English-speaking background: not speaking fluent English before 10 years old. Hypertension: previous diagnosis and current treatment, or either systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg (as per JNC-7 values) [28]. Coronary artery disease: previous diagnosis of heart attack or angina. Other heart disease: previous diagnosis of cardiac arrhythmia, cardiomyopathy, or heart valve disease. Diabetes: declaration of, or taking medication for, diabetes, or fasting blood glucose >7.0 mmol/L. History of depression: previous diagnosis and treatment. Mental activity: average days/week of current participation in 13 listed activities (e.g., reading books). Physical activity: sum of current participation across 8 listed activities (e.g., bicycling), any valid other activity (e.g., yoga), and walking. Social activity: average number of current face-to-face contacts with friends or relatives per month; categorised as low if <5. Health status: self-reported as poor, fair, good, very good or excellent; categorised as low if either poor or fair. Alcohol drinker: drinking at least “monthly or less” rather than “not at all” in the past year. Ever smoker: past or current smoker. Vision: self-reported as adequate or inadequate for all purposes with glasses on. Estimated glomerular filtration rate (eGFR); calculated as 175 × (serum creatinine [μmol/L] × 0.0113)−1.154 × age−0.203, further multiplied by 0.742 for females; categorised as low if <60 ml/min/1.73m².

Statistical Analysis
Descriptive statistics were computed, sex comparisons made using either t- or χ² tests, and associations with age investigated using Pearson correlations or r-tests. For each cognitive performance measure, general linear models (GLMs) adjusted for age and sex were used to identify baseline factors associated with longitudinal change, calculated as follow-up z-scores minus baseline z-scores. Factors with p<0.1 were entered into a multivariable GLM that included age and sex if not already present, and that was reduced stepwise until only factors with p<0.05 remained significant main effect factors. For all baseline factors, we also ran a GLM containing age and sex interaction
Table 1. Baseline characteristics of the study participants.

| Characteristic         | Whole sample | Women | Men              | Age association |
|------------------------|--------------|-------|------------------|-----------------|
| **Sociodemographic**   |              |       |                  |                 |
| Age, mean (SD), y      | 78.59 (4.75) | 78.60 (4.87) | 78.59 (4.60) | –               |
| Males                  | 408 (45.9)   | –     | –                | d = 0.01        |
| Education, mean (SD), y| 11.68 (3.49) | 11.13 (3.05) | 12.33 (3.85)* | r = –0.035      |
| Married                | 43.0         | 134 (27.9) | 247 (60.7)*     | d = –1.28*      |
| NESB                   | 16.2         | 71 (14.8)  | 73 (17.9)       | d = 1.17*       |
| **Cardiac health**     |              |       |                  |                 |
| Hypertension           | 738 (83.0)   | 382 (79.4) | 356 (87.3)*     | d = 1.14*       |
| Antihypertensives      | 522 (41.3)   | 266 (53.3) | 256 (62.7)*     | d = 0.73*       |
| Coronary artery disease| 166 (18.7)   | 56 (11.6)  | 110 (27.0)*     | d = 1.86        |
| Atrial fibrillation    | 53 (6.0)     | 19 (4.0)  | 34 (8.5)*       | d = –0.67       |
| Other heart disease    | 102 (11.5)   | 42 (8.7)  | 60 (14.7)*      | d = 0.84        |
| Systolic BP, mean (SD), mmHg | 144.82 (20.22) | 143.07 (20.45) | 146.85 (19.77)* | r = 0.141* |
| Diastolic BP, mean (SD), mmHg | 82.07 (10.71) | 81.88 (10.06) | 82.28 (11.42) | r = –0.055      |
| **Physical health**    |              |       |                  |                 |
| BMI, mean (SD), kg/m²  | 27.10 (4.46) | 26.68 (4.65) | 27.59 (4.17)* | r = –0.123*     |
| Diabetes               | 128 (14.40)  | 47 (9.8)  | 81 (19.9)*      | d = 0.26        |
| Hypoglycemics          | 78 (8.8)     | 27 (5.6)  | 51 (12.5)*      | d = –0.45       |
| Hypercholesterolemia   | 536 (60.5)   | 290 (60.4) | 246 (60.6)      | d = –0.88*      |
| Hypolipidemics         | 457 (51.4)   | 226 (47.0) | 231 (56.6)*     | d = –0.30       |
| Stroke                 | 35 (4.0)     | 12 (2.5)  | 23 (5.7)*       | d = 0.13        |
| Migraines              | 137 (15.4)   | 104 (21.7) | 33 (8.1)*       | d = –1.23*      |
| Kidney disease         | 20 (2.3)     | 4 (0.8)   | 16 (3.9)*       | d = 1.67        |
| Arthritis              | 480 (54.5)   | 275 (57.8) | 205 (50.7)*     | d = –0.41       |
| Anemia                 | 47 (5.3)     | 14 (2.9)  | 33 (8.1)        | d = –0.55       |
| **Mental health**      |              |       |                  |                 |
| GDS score, mean (SD)   | 2.18 (1.97)  | 2.05 (1.75) | 2.33 (2.18)* | r = 0.133*      |
| History of depression  | 133 (15.0)   | 80 (16.6) | 53 (13.0)       | d = –0.90*      |
| Antidepressants        | 82 (9.2)     | 54 (11.2) | 28 (6.9)*       | d = –0.03       |
| Antianxiety agents     | 41 (4.6)     | 29 (6.0)  | 12 (2.9)*       | d = 1.80*       |
| **Lifestyle**          |              |       |                  |                 |
| Alcohol drinker        | 783 (88.2)   | 407 (84.8) | 376 (92.2)*     | d = –0.70       |
| Ever smoker            | 478 (53.9)   | 203 (42.3) | 275 (67.6)*     | d = 0.24        |
| Mental activity, mean (SD) | 2.53 (0.86) | 2.52 (0.86) | 2.53 (0.86) | r = –0.152*     |
| Physical activity, mean (SD) | 1.66 (1.13) | 1.57 (1.12) | 1.77 (1.14)* | r = –0.208*     |
| Low social activity    | 116 (13.4)   | 56 (11.9)  | 60 (15.2)       | d = 0.26        |
| **General health**     |              |       |                  |                 |
| Low health status      | 132 (14.9)   | 64 (13.3)  | 68 (16.7)       | d = 0.74        |
| 6-m walk time, mean (SD), s | 9.12 (2.81) | 9.36 (3.07) | 8.84 (2.44)* | r = 0.296*      |
| BSIT score, mean (SD)  | 9.30 (2.13)  | 9.72 (1.79) | 8.81 (2.39)* | r = –0.207*     |
| Inadequate vision      | 82 (9.3)     | 51 (10.7)  | 31 (7.6)        | d = 0.67        |
| **Laboratory measures**|              |       |                  |                 |
| APOE e4 carrier        | 197 (22.6)   | 105 (22.3) | 92 (22.8)       | d = –0.77*      |
| Homocysteine, mean (SD), μmol/L | 11.34 (3.96) | 10.62 (4.01) | 12.13 (3.76)* | r = 0.243*      |
| Cholesterol, mean (SD), mmol/L | 4.73 (0.99) | 4.97 (0.98) | 4.45 (0.93)* | r = –0.020      |
| Low eGFR               | 296 (35.6)   | 166 (37.6) | 130 (33.3)      | d = 2.33*       |

APOE = apolipoprotein E; BMI = body mass index; BP = blood pressure; BSIT = Brief Smell Identification Test; eGFR = estimated glomerular filtration rate; GDS = Geriatric Depression Scale; NESB = non-English-speaking background.

*Data are presented as No. (%), unless otherwise indicated.

Maximum n for the whole sample is 889; minimum is 820 (homocysteine).

For categorical factors, d is the difference in mean age of those meeting the factor versus those not meeting the factor. For continuous factors, r is the correlation coefficient with age.

* p < 0.05 for men versus women (t- or χ² tests) or age associations (t- tests or Pearson correlations).

doi:10.1371/journal.pone.0065841.t001
Factors Associated with Cognitive Decline

Risk factors. Table 3 shows the factors significantly associated with cognitive decline and incident MCI or dementia. Factors differed among the outcome measures, but poorer smelling ability and older age featured frequently as risk factors. Poorer smelling ability was associated with increased chances of incident MCI or dementia and greater declines in executive function, memory and global cognition. Older age predicted greater declines in memory, attention/processing speed and global cognition. Older age also emerged as a risk factor in specific subgroups (interaction results in Table 3); it was associated with greater declines in global cognition among participants with history of stroke, in attention/processing speed among migraine sufferers, and in memory among participants with coronary artery disease. Being male was associated with an increased risk of incident MCI or dementia. There were also risk factors identified as specific to men. These included an increased risk of incident MCI or dementia in men with more physical activity (B = 0.366, SE = 0.132, p = 0.006) and significant decline in memory if having ever smoked (B = −0.190, SE = 0.088, p = 0.031). Conversely, poorer smelling ability was a risk factor for incident MCI or dementia primarily in women (B = −0.281, SE = 0.082, p = 0.001).

Protective factors. Marriage protected against declines in executive function and reduced the risk of incident MCI or dementia, whereas both kidney disease and antidepressant use were associated with less memory decline (Table 3). Sex-specific protective factors were found, with men being at reduced risk of incident MCI or dementia if having either diabetes (B = −1.184, SE = 0.550, p = 0.031) or low eGFR (B = −0.385, SE = 0.037). Men also showed less decline in attention/processing speed if taking antidepressants (B = 0.241, p = 0.01) and in executive function if reporting low health status (B = 0.167, p = 0.011). Some protective factors were age-related (interaction results in Table 3). Older age was associated with less global cognitive decline among participants taking antidepressants or those reporting more social activity. Older age was also associated with less memory decline among participants with history of depression, and with reduced chances of incident MCI or dementia among participants with low eGFR.

Additional factors that varied with sex. Table 3 shows associations with cognitive decline that differed between men and women but were not significant within either of these: diastolic blood pressure and memory, low eGFR and global cognition, and visual adequacy and attention/processing speed.

Population Attributable Risks

The PARs (and corresponding ORs and 95% CIs) for baseline factors independently associated with incident MCI or dementia

---

**Table 2. Change in cognitive performance.**

| Measure | Whole sample | Women | | Men | | Correlation with age |
|---------|--------------|-------|-------|-------|-------|----------------------|
|         | Mean (SD)    | n     | Mean (SD) | n | Mean (SD) | n | r | p |
| Attention/PS | −0.20 (1.01) | 838 | −0.17 (0.92) | 449 | −0.24 (1.11) | 389 | −0.100 | .004 |
| Executive | −0.27 (1.07) | 769 | −0.23 (0.96) | 413 | −0.31 (1.19) | 388 | −0.142 | <.001 |
| Memory | −0.16 (0.78) | 847 | −0.14 (0.75) | 459 | −0.19 (0.81) | 388 | −0.155 | <.001 |
| Global | −0.27 (0.77) | 865 | −0.24 (0.66) | 466 | −0.30 (0.88) | 399 | −0.149 | <.001 |

PS = processing speed.

Values are presented as follow-up z-scores minus baseline z-scores; all are significantly less than zero (p < .001).

Pearson correlations using the whole sample.

[doi:10.1371/journal.pone.0065841.t002]
are shown in Table 4. Risks attributable to either being male (PAR = 31.3%) or having poorer smelling ability (PAR = 18.3%) were offset to at least some degree by marriage (PAR = -24.6%). The PARs of factors associated with a decline in cognitive performance are detailed in Table S1, with only the salient results outlined here. Older age (>81 years) had impacts on both less and more severe decline in global cognition (PAR = 24.4% and 27.7%), attention/processing speed (PAR = 24.2% and 21.4%), and memory (PAR = 30.5% and 49.5%). Other salient impacts included coronary artery disease on more severe memory decline (PAR = 30.1%), arthritis and poorer smelling ability on less severe memory decline (PAR = 29.1% and 17.3%, respectively), stroke on more severe global cognitive decline (PAR = 8.7%), and high homocysteine level on less severe executive function decline (PAR = 9.7%). The results of our study are summarized in Figure 1, which shows all factors significantly associated with at least one outcome measure and indicates those with a salient PAR.

### Missing Participants

We conducted subsidiary analyses comparing participants lost to follow-up with those remaining in the study to see if selective attrition could help explain unexpected findings. Compared to men remaining in the study, men lost to follow-up reported less baseline physical activity (1.37±0.89 vs. 1.77±1.14, t = 2.42, p = 0.016) and higher rates of low health status (28.1% vs. 16.7%, χ² = 4.31, p = 0.038). Low eGFR tended to be more common among individuals lost to follow-up than among those remaining in the study (45.1% vs. 35.6%, χ² = 3.52, p = 0.065).

### Discussion

We previously reported cross-sectional studies of the sample used in the current study that found risk profiles for MCI and its subtypes varied with age and sex [9,10]. In being longitudinal, the current study allows for a more refined interpretation of factors as either increasing or decreasing the risk of cognitive decline. We have also extended upon our earlier work by investigating decline within particular cognitive domains.

### Risk and Protective Factors for Late-life Cognitive Decline

A number of risk and protective factors for late-life cognitive decline were identified, with the most prominent being age and smelling ability (others are summarized in Figure 1). Older age predicted greater declines in attention/processing speed, memory and global cognition, and poorer smelling ability predicted greater declines in executive function, memory, and global cognition, as well as the development of incident MCI or dementia. This is consistent with previous reports of both age [30] and poorer smelling ability [8,11–13] being associated with cognitive decline. Many of our findings are also consistent with expectation and/or known mechanisms. For example, the association between poorer smelling ability and cognitive decline is readily accounted for by known mechanisms. For example, the association between poorer smelling ability and cognitive decline is readily accounted for by known mechanisms. For example, the association between poorer smelling ability and cognitive decline is readily accounted for by known mechanisms.

### Variation with Sex and Age

The current study found a number of associations with cognitive decline that varied with age or sex (see Figure 1). Our results suggest that normal aging processes can compound the effects of factors reported elsewhere as promoting cognitive decline, including stroke [32] and low social activity [7]. Most of the variations with sex entailed a significant association in men but not women. Sex differences could reflect discrepancies in the presence or extent of various risk and protective factors and/or prevalence of outcomes. Men in our study had higher rates of incident MCI or dementia, and differed from women on most of the factors.
investigated, including more frequent heart disease and diabetes, but lower levels of cholesterol.

Null and Unexpected Findings

Some measures not associated with cognitive decline in the present study are reported to be associated with decline elsewhere. This includes the \textit{APOE} \textit{e}4 allele, which is a known risk factor for AD [2], but among non-demented individuals appears to be primarily associated with decline in memory rather than other cognitive domains or global cognition [33–35]. With longer follow-up periods than ours (at least 3 years on average), these studies may have allowed more time for significant levels of memory decline to develop. However, even within the memory domain, a recent study with a population and follow-up period very similar to ours found \textit{APOE} \textit{e}4 was associated with decline in visual memory, but not with decline in visual episodic memory, verbal memory, working memory or a visual/working memory composite [36]. Our finding of no association between \textit{APOE} \textit{e}4 and decline on a composite memory measure is consistent with this. While \textit{APOE} \textit{e}4 reportedly promotes a transition from MCI to AD, its association with MCI itself may be low [4]. This might explain why we found no association between \textit{APOE} \textit{e}4 and incident MCI/dementia, as over 80% of our incident cases were MCI. Other measures may have shown no association with cognitive decline in our study because their most salient effects are generated during earlier periods of the lifespan. This includes cholesterol [37] and BMI [38], for both of which late life cognitive impairment has been associated with high levels specifically in mid life.

In some cases the direction of our findings was unexpected, including more educated participants exhibiting greater decline in attention/processing speed. While this seems inconsistent with the concept of cognitive reserve [39], it is similar to previous reports of more educated individuals experiencing greater decline in verbal memory [5] and processing speed [40]. More extensive education may serve to delay the onset of cognitive decline, with this beginning at an earlier age in less educated individuals and missed by our study, or may be associated with higher baseline

\begin{figure}
\centering
\includegraphics[width=\textwidth]{Figure1}
\caption{Factors associated with cognitive decline. Interventions modifying factors with a significant population attributable risk might greatly reduce population-wide cognitive decline. Age and sex interactions suggest further benefits by tailoring interventions to particular demographic groups. doi:10.1371/journal.pone.0065841.g001}
\end{figure}
Domain Specificity

As reported here, previous studies investigating decline across multiple cognitive domains have found that factors associated with decline on at least one domain are not associated with decline on others [5–8]. This is theoretically accounted for by different cognitive processes having different neurological and experiential substrates, and therefore being more or less susceptible to particular factors depending on the mechanisms involved. For example, a previous cross-sectional study found that remitted depression was associated with cognitive deficits primarily involving attention and processing speed [48]. Our finding of greater decline in attention/processing speed for participants with history of depression could be an extension of this (noting that we also found a more complex history of depression by age interaction for the memory domain). Conversely, we did not identify an expected positive association between physical activity and executive functioning [49], potentially for the methodological reasons already outlined. This highlights the broader problem of considerable variation in how particular domains are reported to be affected by particular factors. For example, at least three other studies [8,12,13] have found poorer smell predictive of greater memory decline. Conversely, while we and another study [12] found poorer smell also predictive of executive function decline, a further study did not [13]; and while one study [8] found an association between odor identification and processing speed, we did not. Inconsistency in how tests are assigned to domains likely contributes to this problem (a digit symbol task was assigned to attention/processing speed by us and one other study [8] but to executive functioning by another [13]). This restricts the reliability of domain-specific findings from this and other studies, in addition to limiting the ability to meaningfully compare results across studies. Accordingly, understanding how particular factors affect different types of cognition may be facilitated by future reports including results for individual neuropsychological tests, as an alternative or in addition to those for cognitive domains.

Population Attributable Risks

Identifying factors that influence cognitive decline is essential for developing interventions. We calculated PARs as indicators of where interventions should be targeted so as to maximise population-wide benefits. The largest PARs were for age. Sex and marital status also had large PARs. Potentially modifiable factors with relatively large PARs included coronary artery disease, arthritis, stroke, and high homocysteine. Redoubling efforts to treat or prevent these conditions would contribute greatly to minimising late-life cognitive decline within the population.

Limitations

Non-random attrition of less healthy participants and a reliance on self-report measures have already been discussed as limitations of this study. Another limitation is having only a single 2-year follow-up assessment, which invites noise associated with the instability of MCI diagnoses [50] and cognitive performance scores regressing to the mean. Excluding individuals regaining normal cognition after the 2-year follow-up would help address these issues. A 2-year follow-up may also not allow slow acting factors to be identified. These concerns mean that our null and unexpected findings not matching previously reported associations or readily explained by known mechanisms should be treated cautiously. Further limitations of our study include not considering interactions beyond those involving sex and age. Reports of interactions between other factors, like physical activity and APOE genotype [51], demonstrate further complexity to the etiology of late-life cognitive decline. Lastly, our results may not be generalizable to all elderly populations, and we expect that different but overlapping factors will emerge in different cohorts. For example, a recent study [7] contrasts with ours in finding that participation in any of mental, physical or social activities protected against decline in one or more cognitive domains. However, the cohort was rural Chinese residents, who differed from our sample on many factors, including much lower levels of education and a far higher proportion of smokers.

Conclusions and Implications

Highlights of this study are having demonstrated that factors associated with late-life cognitive decline vary with age, sex and outcome measure, and the identification of PARs for which interventions can be applied. The variations in risk and protective factors we found could help explain the inconsistent and poor support for particular factors in the literature. Effects of age and
sex may be overlooked when these are adjusted for in statistical procedures rather than investigated as potential interactions or with stratified analyses. These results also suggest that etiologies for cognitive decline can differ between men and women and change over the lifespan. With an aging population, the prevalence and societal burden of cognitive impairment is rapidly increasing. Interventions are urgently required. Our identification of PARs suggests that preventing or treating conditions typical of aging might reduce population-wide levels of cognitive decline and impairment. There may be further benefits in tailoring interventions to particular sex and age groups. Future studies that test relevant interventions are needed to establish the extent to which this is true.

**Supporting Information**

**Table S1** PARs for decline in cognitive performance.

**Acknowledgments**

DNA samples were extracted by Genetic Repositories Australia. The APOE genotyping was performed by Arezoo Assareh and Karen Mather in the laboratory of Peter Schofield and John Krook at Neuroscience Research Australia, Sydney, Australia. Blood samples were collected by South Eastern Area laboratory Service. We thank the Sydney Memory and Ageing Study participants. For their essential contribution to the study we also thank the Sydney Memory and Ageing Study Team, the members of which include Allison Bowman, Kim Burns, Anthony Broe, Joula Dekker, Louise Dooley, Michele de Permentier, Sarah Fairjones, Janelle Fletcher, Therese French, Cathy Foster, Emma Nugent-Cleary-Fox, Chien Gooi, Evelyn Harvey, Rebecca Helyer, Sharpley Hsieh, Laura Hughes, Sarah Jacek, Mary Johnston, Kate Maston, Donna McCade, Samantha Meeth, Eveline Milne, Angharad Moir, Ros O'Grady, Kia Pfefelli, Carine Pole, Laura Reuser, Amanda Rose, Peter Schofield, Zeeshan Shahnawaz, Amanda Sharpley, Claire Thompson, Wiebke Queisser, and Sam Wong (all are affiliated with the Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine, University of New South Wales, Australia).

**References**

1. Millan-Calenti JC, Tubio J, Pita-Fernandez S, Rochette S, Lorenzo T, et al. (2012) Cognitive impairment as predictor of functional dependence in an elderly sample. Arch Gerontol Geriatr 54: 197–201.
2. Plassman BL, Williams JW Jr, Burke JR, Hobinger T, Benjamin S (2010) Systematic review: factors associated with risk for and possible prevention of cognitive decline in later life. Ann Intern Med 153: 192–193.
3. Arntzen KA, Schirmer H, Wåhsgaard T, Mathiesen ER (2011) Impact of cardiovascular risk factors on cognitive function: The Tromso study. Eur J Neurol 18: 737–743.
4. Arteo S, Anselmi ML, Portet F, Dupuy A, Berr C, et al. (2008) Risk profiles for mild cognitive impairment and progression to dementia are gender specific. J Neurol Neurosurg Psychiatry 79: 979–984.
5. Alley D, Suthers K, Grimmins E (2007) Education and cognitive decline in older Americans: Results from the AHEAD sample. Res Aging 29: 73–94.
6. Buchman AS, Tanne D, Boyle PA, Shah RC, Leurgans SE, et al. (2009) Kidney function is associated with the rate of cognitive decline in the elderly. Neurology 73: 920–927.
7. Wang HX, Jin Y, Hendrie HC, Liang C, Yang L, et al. (2013) Late life leisure activities and risk of cognitive decline. J Gerontol A Biol Sci Med Sci 68: 205–213.
8. Wilson RS, Arnold SE, Tang Y, Bennett DA (2006) Odor identification and cognitive decline in very elderly retirees. Neuroepidemiology 21: 68–73.
9. Sachdev PS, Lipnicki DM, Crawford J, Reppermund S, Kochan NA, et al. (2010) Risk profiles of subtypes of mild cognitive impairment: the Sydney memory and ageing study. J Am Geriatr Soc 60: 135–143.
10. Sachdev PS, Lipnicki DM, Crawford J, Reppermund S, Kochan NA, et al. (2012) Risk Profiles for Mild Cognitive Impairment Vary by Age and Sex: The Sydney Memory and Ageing Study. Am J Geriatr Psychiat 20: 854–863.
11. Graves AB, Bowen JD, RajaRajam L, McCormick WC, McCurry SM, et al. (1999) Impaired olfaction as a marker for cognitive decline: interaction with apolipoprotein E epsilon 4 status. Neurology 53: 1480–1487.
12. Royal DR, Chiado LK, Polk MS, Jaramillo CJ (2002) Severe dysosmia is specifically associated with Alzheimer-like memory deficits in nondemented elderly retirees. Neuroepidemiology 21: 68–73.
13. Swan GE, Carmelli D (2002) Impaired olfaction predicts cognitive decline in nondemented older adults. Neuroepidemiology 21: 58–67.
14. Sachdev PS, Brodaty H, Reppermund S, Kochan NA, Troller JN, et al. (2010) The Sydney Memory and Ageing Study (MAS): methodology and baseline medical and neuropsychiatric characteristics of an elderly epidemiologically non-demented cohort of Australians aged 70–90 years. Int Psychogeriatr 22: 1248–1264.
15. Folstein MF, Folstein SE, McHugh PR (1975) ‘‘Mini-mental state’’. A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 12: 189–198.
16. Anderson TM, Sachdev PS, Brodaty H, Troller JN, Andrews G (2007) Effects of sociodemographic and health variables on Mini-Mental State Exam scores in older Australians. Am J Geriatr Psychiatry 15: 467–476.
17. Wechsler D (1997) Wechsler Adult Intelligence Scale-III. San Antonio, TX: The Psychological Corporation.
18. Strauss E, Sherman EMS, Spreen O (2006) A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. New York, NY: Oxford University Press.
19. Wechsler D (1997) Wechsler Memory Scale-3rd Edition Manual. San Antonio, TX: The Psychological Corporation.
20. Benton AL, Swan AB, Spreen O (1996) Der Benton Test [The Benton Test]. Bern, Switzerland: Huber.
21. Kaplan E (2001) The Boston Naming Test. Philadelphia, PA: Lippincott, Williams & Wilkins.
22. Winblad B, Palmner K, Krupeto M, Jelic V, Fratiglioni L, et al. (2004) Mild cognitive impairment beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256: 240–246.
23. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders: DSM-IV-TR. Washington, DC: American Psychiatric Association.
24. Hindmarsh I, Lefebv H, de Jongh P, Erzigkeit H (1998) The Bayer Activities of Daily Living Scale (b-ADL). Dement Geriatr Cogn Disord 9: 20–26.
25. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, et al. (1983) Development and validation of a geriatric depression screening scale - a preliminary-report. J Psychiat Res 17: 37–49.
26. Waite LM, Broe GA, Grayson DA, Creasey H (2001) Preclinical syndromes predict dementia: the Sydney elderly persons study. J Neurosurg Psychiatry 71: 296–302.
27. Doty RL, Marcus A, Lee WW (1996) Development of the 12-item Cross-Cultural Smell Identification Test (CC-CIFT). Laryngoscope 106: 353–356.
28. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, et al. (2003) The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289: 2560–2572.
29. Barnes BB, Steindorf K, Hein R, Flech-Jansy D, Chang-Chauve J (2011) Population attributable risk of invasive postmenopausal breast cancer and breast cancer subtypes for modifiable and non-modifiable risk factors. Cancer Epidemiol 35: 345–352.
30. Heudric HC, Albert MS, Butters MA, Gao S, Knapman DS, et al. (2006) The NIH Cognitive and Emotional Health Project. Report of the Critical Evaluation Study Committee. Alzheimers Dement 2: 12–32.
31. Christen-Zaech S, Kraftsik R, Pillevuit O, Kiraly M, Martins R, et al. (2003) Early olfactory involvement in Alzheimer’s disease. Can J Neuro Sci 30: 20–25.
32. Sachdev PS, Brodaty H, Valenzuela MJ, Lorenz LM, Koschera A (2004) Progression of cognitive impairment in stroke patients. Neurology 63: 1618–1623.
33. Bunce D, Fratiglioni L, Small BJ, Winblad B, Buckman L (2004) APOE and cognitive decline in preclinical Alzheimer disease and non-demented ageing. Neurology 63: 816–821.
34. Caselli RJ, Duerck AG, Osborne D, Sababgh MM, Connor DJ, et al. (2009) Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med 361: 251–263.
35. Packard CJ, Westendorp RG, Scott DJ, Calske MJ, Murray HM, et al. (2007) Association between apolipoprotein E4 and cognitive decline in elderly adults. J Am Geriatr Soc 55: 1777–1785.
36. Lim YY, Ellis KA, Pietrzak RH, Ames D, Darby D, et al. (2012) Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology 79: 1645–1652.
37. Anstey KJ, Lipnicki DM, Low LF (2008) Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry 16: 343–354.
38. Dahl AK, Hassing LB, Fransson EI, Gatz M, Reynolds CA, et al. (2013) Body mass index across midlife and cognitive change in late life. Int J Obes (Lond) 37: 296–302.
39. Stern Y (2002) What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 8: 448–460.
40. Batterham PJ, Mackinnon AJ, Christensen H (2011) The effect of education on the onset and rate of terminal decline. Psychol Aging 26: 339–350.
41. Dash SK (2013) Cognitive Impairment and Diabetes. Recent Pat Endocr Metab Immune Drug Discov 7: 155–165.
42. Dominguez RO, Marschof ER, Gonzalez SE, Repetto MG, Serra JA (2012) Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer’s disease patients. Diabetes Res Clin Pract 98: 68–74.
43. Musico M, Palmer K, Salanoure G, Lugo F, Perri R, et al. (2009) Predictors of progression of cognitive decline in Alzheimer’s disease: the role of vascular and sociodemographic factors. J Neurol 256: 1298–1295.
44. Kuljis RO, Salkovic-Petrisic M (2011) Dementia, diabetes, Alzheimer’s disease, and insulin resistance in the brain: progress, dilemmas, new opportunities, and a hypothesis to tackle intersecting epidemics. J Alzheimers Dis 23: 29–41.
45. Sofi F, Valecchi D, Bacci D, Abbat R, Gensini GF, et al. (2013) Physical activity and risk of cognitive decline: a meta-analysis of prospective studies. J Intern Med 260: 107–117.
46. Tyas SL, Tate RB, Wooldrage K, Manfreda J, Strain LA (2006) Estimating the incidence of dementia: the impact of adjusting for subject attrition using health care utilization data. Am J Epidemiol 16: 477–484.
47. Middleton LE, Manini TM, Simmons EM, Harris TB, Barnes DE, et al. (2011) Activity energy expenditure and incident cognitive impairment in older adults. Arch Intern Med 171: 1251–1257.
48. Hasselbalch BJ, Knorr U, Hasselbalch SG, Gade A, Kessing LV (2012) Cognitive deficits in the remitted state of unipolar depressive disorder. Neurropsychology 26: 642–651.
49. Ratey JJ, Loehr JE (2011) The positive impact of physical activity on cognition during adulthood: a review of underlying mechanisms, evidence and recommendations. Rev Neurosci 22: 171–185.
50. Mitchell AJ, Shiri-Feshki M (2008) Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis. J Neurol Neurosurg Psychiatry 79: 1386–1391.
51. Podewiltz LJ, Guallar E, Koller LH, Fried LP, Lopez OL, et al. (2005) Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study. Am J Epidemiol 161: 639–651.